According to the Economist, the U.S. electronic cigarette market is booming, with sales numbering between $300 to $500 million in 2012. While this statistic pales in comparison to the $80 billion market for conventional cigarettes, a drastic upward trend in electronic cigarette sales has been observed since the product’s introduction just several years ago. Sales are projected to continue rising in the coming years.
The Food and Drug Administration (FDA) – which has not yet granted these products its approval due to ongoing testing — observes that electronic cigarettes are designed “to deliver nicotine or other substances to a user in the form of a vapor.” In other words, electronic cigarettes dilute the potency of the nicotine product.
The devices are typically rechargeable and battery powered. Each consists of a heating element, a cartridge containing nicotine or other chemicals, and an atomizer that converts the cartridge contents into vapor. Smokers of conventional cigarettes typically use electronic cigarettes to control or cease their nicotine habit by limiting the intake of the toxin.
Since its relatively recent introduction to the market, electronic cigarettes remain under investigation among experts in the fields of health and science. The benefits and risks of such devices are currently being weighed by the Food and Drug Administration, along with other leading authorities in the public and private sectors.
It is hard to say what influence, precisely, electronic cigarettes hold in guaranteeing the success of a smoker’s cessation. However, a significant amount of observational data has been recorded on the matter.
According to The Huffington Post, “In May, a large study out of England that was published in the journal Addiction made worldwide news when they announced that smokers trying to quit were 60 percent more likely to succeed if they used electronic cigarettes than over-the-counter therapies such as nicotine patches or gum.”